Trial of ARO-HIF2 for Clear Cell Renal Cell Carcinoma Announces Positive Interim Results

The trial has efficiently enrolled 17 sufferers with clear cell renal cell carcinoma and has reported that the drug is properly tolerated at doses of as much as 525 mg weekly.

A part 1b dose-finding examine of ARO-HIF2 for the therapy of sufferers with clear cell renal cell carcinoma (ccRCC) has efficiently enrolled 17 sufferers and has proven that the drug is properly tolerated at doses of as much as 525 mg weekly, in keeping with a press launch.

“The AROHIF21001 part 1b examine is designed to judge security in addition to preliminary pharmacodynamics and efficacy in a sophisticated ccRCC affected person inhabitants,” mentioned James Hamilton, MD, MBA, senior vice chairman of discovery and translational medication at Arrowhead, within the press launch. “We imagine that within the first 2 dose cohorts investigational ARO-HIF2 is exhibiting clear indicators of significant goal engagement and a few doubtlessly early indicators of efficacy in at the least 1 affected person.”

ARO-HIF2 is an investigational RNA interference therapeutic. Arrowhead is presently enrolling the third deliberate affected person cohort for the trial and intends to current addition knowledge quickly. In response to the press launch, 17 sufferers have been enrolled to obtain intravenous injections of both 225 mg weekly (cohort 1, n=7) or 525 mg weekly (cohort 2, n=10). Cohort 3 is presently enrolling sufferers to obtain 1050 mg weekly.

Investigators assessed the HIF2α protein H-score and located that 9 out of 17 sufferers had tumor samples that could possibly be evaluated. Seven of these sufferers demonstrated reductions in HIF2α and reductions ranged from -9% to -82% with a imply discount of -48%.

Efficacy of the drug was assessed utilizing the Response Analysis Standards in Stable Tumors. In cohort 2, one particular person had a partial response with roughly 65% tumor shrinkage and 5 had a finest response of secure illness. Moreover, 4 topics in cohort 2 stay on the drug with secure illness, with therapy durations between 12 and 24 weeks.

As of the reporting date, the investigational drug has been typically properly tolerated at doses as much as 252 mg weekly. No circumstances of anemia associated to the drug have been reported.

“Tumors usually have a excessive degree of heterogeneity and the sufferers in AROHIF21001 have superior ccRCC and have failed a number of traces of therapy together with checkpoint inhibitors and anti-VEGF regimens, so these early ends in a closely pre-treated inhabitants are encouraging for investigational ARO-HIF2 and our tumor-targeted platform broadly,” Hamilton mentioned within the press launch. “ARO-HIF2 has been typically well-tolerated, and we stay up for continued dose escalation.”


Arrowhead Declares Constructive Interim Outcomes Section 1b Research of ARO-HIF2 for Therapy of Clear Cell Renal Cell Carcinoma. Information launch. BusinessWire. July 6, 2021. Accessed July 9, 2021.


Inter Reviewed is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – The content will be deleted within 24 hours.

Related Articles

Back to top button